Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) was $3.56 for the day, up 2.30% from the previous closing price of $3.48. In other words, the price has increased by $2.30 from its previous closing price. On the day, 0.56 million shares were traded. AMLX stock price reached its highest trading level at $3.58 during the session, while it also had its lowest trading level at $3.31.
Ratios:
Our analysis of AMLX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.55 and its Current Ratio is at 4.55. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Robert W. Baird on November 18, 2024, Upgraded its rating to Outperform and sets its target price to $11 from $3 previously.
On October 23, 2024, BofA Securities Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $4.20 to $10.
Mizuho Downgraded its Buy to Neutral on March 18, 2024, whereas the target price for the stock was revised from $32 to $4.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 06 ’25 when Klee Justin B. sold 7,471 shares for $4.04 per share. The transaction valued at 30,202 led to the insider holds 3,176,788 shares of the business.
Cohen Joshua B sold 7,471 shares of AMLX for $30,232 on Jan 06 ’25. The Co-Chief Executive Officer now owns 3,213,098 shares after completing the transaction at $4.05 per share. On Dec 02 ’24, another insider, Bedrosian Camille L, who serves as the Chief Medical Officer of the company, sold 5,421 shares for $5.54 each. As a result, the insider received 30,007 and left with 138,380 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMLX now has a Market Capitalization of 305058912 and an Enterprise Value of 12202382. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.55 while its Price-to-Book (P/B) ratio in mrq is 1.24. Its current Enterprise Value per Revenue stands at 0.062 whereas that against EBITDA is -0.049.
Stock Price History:
The Beta on a monthly basis for AMLX is -0.56, which has changed by -0.7737321 over the last 52 weeks, in comparison to a change of 0.24440956 over the same period for the S&P500. Over the past 52 weeks, AMLX has reached a high of $19.95, while it has fallen to a 52-week low of $1.58. The 50-Day Moving Average of the stock is -21.58%, while the 200-Day Moving Average is calculated to be 17.83%.
Shares Statistics:
AMLX traded an average of 1.16M shares per day over the past three months and 1213470 shares per day over the past ten days. A total of 68.55M shares are outstanding, with a floating share count of 43.43M. Insiders hold about 36.64% of the company’s shares, while institutions hold 67.02% stake in the company. Shares short for AMLX as of 1735603200 were 1942447 with a Short Ratio of 1.68, compared to 1732838400 on 1448789. Therefore, it implies a Short% of Shares Outstanding of 1942447 and a Short% of Float of 3.1199999999999997.
Earnings Estimates
The current rating of Amylyx Pharmaceuticals Inc (AMLX) reflects the combined expertise of 1.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.62, with high estimates of -$0.62 and low estimates of -$0.62.
Analysts are recommending an EPS of between -$4.12 and -$4.47 for the fiscal current year, implying an average EPS of -$4.3. EPS for the following year is -$2.13, with 2.0 analysts recommending between -$1.73 and -$2.54.
Revenue Estimates
A total of 4 analysts have provided revenue estimates for AMLX’s current fiscal year. The highest revenue estimate was $88.04M, while the lowest revenue estimate was $88M, resulting in an average revenue estimate of $88.03M. In the same quarter a year ago, actual revenue was $380.79M
